As the popularity of weight-loss drugs like Ozempic and Wegovy continues to soar, a growing number of employers are considering adding coverage for these medications to their health insurance plans. While traditionally viewed as “lifestyle” drugs, the potential health benefits and cost savings associated with effective weight management are prompting a shift in perspective.
According to the article, major companies like Amazon, Google, and Citigroup have already begun covering GLP-1 drugs like Ozempic for their employees struggling with obesity. This move recognizes the significant impact that obesity can have on overall health and productivity, often leading to increased medical costs and absenteeism.
Employers are weighing the upfront costs of providing these weight-loss medications against the potential long-term savings from reduced healthcare expenses related to obesity-driven conditions like diabetes, heart disease, and certain cancers. Additionally, improved employee well-being and productivity are factors being considered.
However, the article notes that coverage decisions vary widely, with some employers choosing to cover only specific weight-loss drugs or imposing criteria like minimum BMI requirements or prior authorization from health plans.
As the conversation around weight-loss drugs evolves, employers are navigating complex considerations, including costs, potential for misuse, and the need for comprehensive wellness programs alongside pharmacological interventions.
